Testing effectiveness (Phase 2)Study completedNCT04993677What this trial is testingSEA-CD40 Given With Other Drugs in CancersWho this might be right forMelanomaCarcinoma, Non-Small- Cell Lung Seagen Inc. 77
Testing effectiveness (Phase 2)Study completedNCT05342636What this trial is testingCombination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)Who this might be right forEsophageal Squamous Cell Carcinoma (ESCC) Merck Sharp & Dohme LLC 90
Large-scale testing (Phase 3)Study completedNCT02220894What this trial is testingStudy of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)Who this might be right forNon-small Cell Lung Cancer Merck Sharp & Dohme LLC 1,274
Testing effectiveness (Phase 2)Ended earlyNCT04925986What this trial is testingSitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLCWho this might be right forCarcinoma, Non-Small-Cell LungLung DiseasesLung Neoplasms+6 more Sarah Goldberg 9
Testing effectiveness (Phase 2)Looking for participantsNCT06892548What this trial is testingA Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung CancerWho this might be right forAdvanced Lung Cancer BioNTech SE 594
Large-scale testing (Phase 3)Active Not RecruitingNCT05785767What this trial is testingLearn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)Who this might be right forAdvanced Non-Small Cell Lung Cancer Regeneron Pharmaceuticals 850
Large-scale testing (Phase 3)Study completedNCT03850444What this trial is testingStudy of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension StudyWho this might be right forNon-small Cell Lung Cancer Merck Sharp & Dohme LLC 262
Testing effectiveness (Phase 2)Study completedNCT04165083What this trial is testingKEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)Who this might be right forCarcinoma, Non-Small-Cell Lung Merck Sharp & Dohme LLC 102
Testing effectiveness (Phase 2)Study completedNCT03697304What this trial is testingPlatform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid TumoursWho this might be right forNeoplasm MetastasisAdvanced TumorsMetastatic Solid Tumors Boehringer Ingelheim 211
Not applicableLooking for participantsNCT06988592What this trial is testingGemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment (BTC-IM-1)Who this might be right forAdvanced Biliary Tract Cancer Fudan University 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT05557591What this trial is testingA Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)Who this might be right forAdvanced Non-Small Cell Lung Cancer Regeneron Pharmaceuticals 51
Large-scale testing (Phase 3)Looking for participantsNCT05215340What this trial is testingStudy of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic AlterationsWho this might be right forMetastatic Non Small Cell Lung Cancer Daiichi Sankyo 740